AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 222 min read$QURE

Kapusta Matthew C sold $9.4M of QURE

Kapusta Matthew C (CEO, Managing Director) sold 206,100 shares of uniQure N.V. (QURE) at an average of $45.47 ($42.61–$50.00, $9.37M total) across 8 trades over 2026-06-17 to 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kapusta Matthew C
Published Jun 22, 2026, 12:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the CEO’s $9.37M open-market sale executed across 8 trades (2026-06-17 to 2026-06-18) with a stated 10b5-1 plan.

02

Market read

Provides a concrete, time-stamped insider selling datapoint that can influence short-term sentiment but lacks a fundamental trigger in the text.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent positive catalysts (not present here) or follow-on insider buying (not disclosed in this text).

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure CEO Matthew C Kapusta sold $9.37M of QURE shares via an open-market sale under a pre-arranged 10b5-1 plan (Form 4 filed today).

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source Form 4 showing a large sale, yet it explicitly references a pre-arranged 10b5-1 plan, which typically reduces interpretive signal about new information.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated; uniQure is the only subject.

Global

None indicated beyond potential sentiment for the single issuer.

Counterpoint

What could challenge this read

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Kapusta Matthew C

    CEO, Managing Director; reported open-market sale of QURE shares.

  • trading mechanism
    Rule 10b5-1 plan

    Pre-arranged plan cited as the basis for the insider’s sales.

Read at source← All news

Related articles

AUG 8
$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

aol.com8 min
AUG 6
$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

fabrydiseasenews.com5 min
JUL 29
$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

investing.com6 min
JUL 29
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

finanznachrichten.de6 min
JUL 29
$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

SEC EDGAR 8-K6 min
JUN 25
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.

finanznachrichten.de2 min